Haupt E, Herrmann R, Benecke-Timp A, Vogel H, Hilgenfeldt J, Haupt A, Walter C
Saale-Klinik der BfA, Bad Kissingen, Germany.
Exp Clin Endocrinol Diabetes. 1996;104(6):420-30. doi: 10.1055/s-0029-1211480.
The Kissingen Diabetes Intervention Study (KID) evaluated 1050 diabetic patients of the German Federal Insurance Institution for Salaried Employees (BfA) admitted for inpatient rehabilitation. The data for the prospective longitudinal study (which was collected in a single center) relate to the structure of the patient cohort, socio-economic and psychological factors and the mode of medical management at the time of admission and discharge. Data regarding the same variables was checked by random testing six and twelve months after discharge and used in this part of the study. This cohort of patients is especially interesting for aspects of health policy because it comprises rather young diabetics engaged in highly qualified professional work. Therapy modifications entailing a more intensive insulin regimen were necessary in 20.7% of all type I diabetics. Most of these alterations were maintained over the following 12 months of management by the general practitioner. Improvement of HbA1 levels was related to the number of daily insulin administrations. The results obtained during inpatient treatment in patients on ICT are maintained even one year after their discharge. For type I diabetics, the first training measure especially results in a long-term improvement of the metabolic situation, whereas patients who have already received training several times previously benefit continuously less with increasing repetition of training. After twelve months the intensified insulin therapy of type I diabetics had no further effect on the BMI or the already previously normal serum lipids. In 55.5% of all type II diabetics, the therapy had to be modified. Inpatient rehabilitation resulted in raising the low number of type II diabetics treated just with diet by 5.3%. This proportion was again slightly reduced 12 months later. During inpatient residence the number of overweight type II diabetics treated with drugs was reduced both in the group on oral hypoglycemics and in the group on pre-mixed insulin, according to the weight loss achieved. On the other hand, it was often necessary to intensify the usual insulin regimen twice daily in the group of younger patients with normal body weight. These modifications were maintained twelve months after the stay in hospital for most of these patients. Virtually all type II diabetics on oral hypoglycemics are overweight as a reflection of too early prescriptions of oral hypoglycemics which often neglects the chance of a dietary management only. In this group, therapy modifications were directed towards treatment with diet only and with oral hypoglycemics having an extra-pancreatic action. On metformin, the HbA1 was reduced by 0.3% and the BMI by 0.9 kg/m2 even 12 months later. In the 90% of type II diabetics previously treated with sulphonylureas (almost exclusively glibenclamide), re-modification of therapy from metformin back to the old regimen (16:9%) was especially high. This is probably due to the uncertainty with and general restrictions in the prescription of metformin in the relevant period 1991 to 1995. The results 12 months after inpatient treatment show the small improvement of HbA1 and serum lipids as already seen in other larger interventional studies. The BMI does not change significantly within the relatively short follow-up period. The best long-term results are achieved by a combined therapy with sulphonylurea compounds and metformin. The KID study demonstrates major deficits in intensifying the insulin regimen of type I diabetics and in the individual adaptation to therapy of type II diabetes in Germany, even when younger patients of higher professional status are considered. Interventional inpatient rehabilitation improves their metabolic situation with lasting effect and can compensate deficits in outpatient management by the general practitioner. However, future concepts have to be improved at all levels of diabetic management, with a view to achieving an optimum interaction.
基辛根糖尿病干预研究(KID)对德国联邦受薪雇员保险机构(BfA)收治的1050例糖尿病患者进行了住院康复评估。这项前瞻性纵向研究(在单一中心收集数据)的数据涉及患者队列结构、社会经济和心理因素以及入院和出院时的医疗管理模式。出院后6个月和12个月通过随机检测对相同变量的数据进行了检查,并用于本研究的这一部分。这组患者在卫生政策方面特别具有研究价值,因为其中包括从事高素质专业工作的相对年轻的糖尿病患者。20.7%的所有I型糖尿病患者需要进行治疗调整,采用更强化的胰岛素治疗方案。在随后由全科医生管理的12个月中,这些调整大多得以维持。糖化血红蛋白(HbA1)水平的改善与每日胰岛素注射次数有关。接受胰岛素持续皮下输注(ICT)治疗的患者在住院治疗期间取得的结果,即使在出院一年后仍能维持。对于I型糖尿病患者,首次训练措施尤其能带来代谢状况的长期改善,而之前已经接受过多次训练的患者,随着训练次数的增加,获益持续减少。12个月后,I型糖尿病患者强化胰岛素治疗对体重指数(BMI)或之前已正常的血脂没有进一步影响。55.5%的所有II型糖尿病患者需要调整治疗方案。住院康复使仅接受饮食治疗的少数II型糖尿病患者比例提高了5.3%。12个月后,这一比例再次略有下降。在住院期间,根据体重减轻情况,口服降糖药组和预混胰岛素组中接受药物治疗的超重II型糖尿病患者数量均有所减少。另一方面,在体重正常的年轻患者组中,通常需要将每日两次的常规胰岛素治疗方案强化。这些患者出院12个月后,大多数患者的这些调整得以维持。几乎所有服用口服降糖药的II型糖尿病患者都超重,这反映出口服降糖药处方过早,往往忽略了仅通过饮食管理的可能性。在这组患者中,治疗调整主要针对仅采用饮食治疗以及使用具有胰腺外作用的口服降糖药。即使在12个月后,使用二甲双胍治疗,糖化血红蛋白降低了0.3%,体重指数降低了0.9kg/m²。在之前接受磺脲类药物(几乎全是格列本脲)治疗的90%的II型糖尿病患者中,从二甲双胍治疗重新调整回旧治疗方案(16:9%)的比例特别高。这可能是由于在1991年至1995年相关期间,二甲双胍处方存在不确定性和普遍限制。住院治疗12个月后的结果显示,糖化血红蛋白和血脂有小幅改善,这在其他更大规模的干预研究中也已观察到。在相对较短的随访期内,体重指数没有显著变化。磺脲类化合物与二甲双胍联合治疗可取得最佳长期效果。基辛根糖尿病干预研究表明,即使考虑到专业地位较高的年轻患者,德国在强化I型糖尿病患者的胰岛素治疗方案以及II型糖尿病的个体化治疗方面仍存在重大缺陷。住院干预康复可改善他们的代谢状况,并产生持久效果,还可弥补全科医生门诊管理的不足。然而,未来的理念必须在糖尿病管理的各个层面加以改进,以期实现最佳的相互作用。